“Law360's Pay-For-Delay Cheat Sheet for 2017,” Law360
January 17, 2017
Case: In re: Lidoderm Antitrust Litigation Court: Northern District of California, U.S. District Court Judge William H. Orrick Drug: Lidoderm, pain patch Status: Awaiting class certification ruling
This case accusing Endo Pharmaceuticals of paying Watson Pharmaceuticals to delay its launch of a generic version of the lidocaine pain patch is going forward with the bulk of its antitrust claims intact following a battery of largely unsuccessful motions to dismiss in 2014. The judge told both sides after a November hearing that hewas inclined to certify a class of indirect purchasers in the case but has not yet ruled on the motions. A jury trial is currently set for December.